Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day

Current Infectious Disease Reports

Volumn 19, Issue 3, 2017, Pages

  Collins, Natalie D ^a   Barrett, Alan D T ^b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Angola; Democratic Republic of Congo; Flavivirus; Fractional dosing; Vaccine; Yellow fever

Indexed keywords

LIVE VACCINE; YELLOW FEVER VACCINE;

AFRICA; EMERGENCY CARE; ENDEMIC DISEASE; EPIDEMIC; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; REVIEW; YELLOW FEVER;

EID: 85014901202     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-017-0566-9     Document Type: Review

References (44)

1. Monath TP, Vasconcelos PF. Yellow fever. J Clin Virol. 2013;64:160–73.
2. •• Garske T, Van Kerkhove MD, Yactayo S, Olivier R, Lewis RF, Staples JE, et al. Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med. 2014;11:e1001638. The most current morbidity and mortality rates of yellow fever virus in Africa.
3. Barrett AD, Higgs S. Yellow fever: a disease that has yet to be conquered. Annu Rev Entomol. 2007;52:209–29.
4. Lai S, Huang Z, Zhou H, Anders KL, Perkins TA, Yin W, et al. The changing epidemiology of dengue in China, 1990–2014: a descriptive analysis of 25 years of nationwide surveillance data. BMC Med. 2015;13:100.
5. Bryant JE, Holmes EC, Barrett AD. Out of Africa: a molecular perspective on the introduction of yellow fever virus into the Americas. PLoS Pathog. 2007;3, e75.
6. Beck A, Guzman H, Li L, et al. Phylogeographic reconstruction of African yellow fever virus isolates indicates recent simultaneous dispersal into east and west Africa. PLoS Negl Trop Dis. 2013;7, e1910.
7. World Health Organization. Yellow fever, 05.2016 http://www.who.int/mediacentre/factsheets/fs100/en/. 2016.
8. World Health Organization. Global Strategy to Elimate Yellow Fever Epidemics (EYE), 9.26.2016. http://www.who.int/immunization/sage/meetings/2016/october/2_EYE_Strategy.pdf?ua=1. 2016.
9. Pugachev KV, Guirakhoo F, Ocran SW, Mitchell F, Parsons M, Penal C, et al. High fidelity of yellow fever virus RNA polymerase. J Virol. 2004;78:1032–8.
10. Beck A, Tesh RB, Wood TG, Widen SG, Ryman KD, Barrett AD. Comparison of the live attenuated yellow fever vaccine 17D-204 strain to its virulent parental strain Asibi by deep sequencing. J Infect Dis. 2014;209:334–44.
11. Tangy F, Desprès P. Yellow fever vaccine attenuation revealed: loss of diversity. J Infect Dis. 2014;209:318–20.
12. Salmona M, Gazaigne S, Mercier-Delarue S, Garnier F, Korimbocus J, de Verdière NC, et al. Molecular characterization of the 17D-204 yellow fever vaccine. Vaccine. 2015;33:5432–6.
13. Bonaldo MC, Sequeira PCC, Galler R. The yellow fever 17D virus as a platform for new live attenuated vaccines. Hum Vaccin Immunother. 2014;10:1256–65. doi:10.4161/hv.28117.
14. Barrett AD, Teuwen DE. Yellow fever vaccine—how does it work and why do rare cases of serious adverse events take place? Curr Opin Immunol. 2009;21:308–13.
15. Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-Mouhim A, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med. 2008;205:3119–31.
16. Luiza-Silva M, Campi-Azevedo AC, Batista MAA, Martins MA, Avelar RS, da Silveira D, et al. Cytokine signatures of innate and adaptive immunity in 17DD yellow fever vaccinated children and its association with the level of neutralizing antibody. J Infect Dis. 2011;204:873–83.
17. Silva ML, Martins MA, Espírito-Santo LRR, Campi-Azevedo AC, Silveira-Lemos D, Ribeiro JGG, et al. Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults. Vaccine. 2011;29:583–92.
18. Quaresma JA, Pagliari C, Medeiros DB, Medeiros DB, Duarte MI, Vasconcelos PF. Immunity and immune response, pathology and pathologic changes: progress and challenges in the immunopathology of yellow fever. Rev Med Virol. 2013;23:305–18.
19. Gotuzzo E, Yactayo S, Córdova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013;89:434–44.
20. Blom K, Braun M, Ivarsson MA, Gonzalez VD, Falconer K, Moll M, et al. Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response. J Immunol. 2013;190:2150–8.
21. • Watson AM, Lam LK, Klimstra WB, Ryman KD. The 17D-204 vaccine strain-induced protection against virulent yellow fever virus is mediated by humoral immunity and CD4+ but not CD8+ T cells. PLoS Pathog. 2016;12:e1005786. An in vivo mouse study that details the immune response following vaccination with 17D-204 which suggest cellular immunity, specifically, CD4 cells contribute to protection from wild-type infection.
22. James EA, LaFond RE, Gates TJ, Mai DT, Malhotra U, Kwok WW. Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins. J Virol. 2013;87:12794–804.
23. Wieten RW, Goorhuis A, Jonker EFF, de Bree GJ, de Visser AW, van Genderen JJ, et al. 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients. J Infect. 2016;72:713–22.
24. Fuertes Marraco SA, Soneson C, Cagnon L, Gannon PO, Allard M, Maillard SA, et al. Long-lasting stem cell-like memory CD8+ T cells with a naïve-like profile upon yellow fever vaccination. Sci Transl Med. 2015;7:282ra48.
25. Akondy RS, Johnson PL, Nakaya HI, Edupuganti S, Mulligan MJ, Lawson B, et al. Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination. Proc Natl Acad Sci U S A. 2015;112:3050–5.
26. Staples JE, Gershman M, Fischer M. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59:1–27.
27. Collaborative group for studies on yellow fever vaccines. Duration of post-vaccination immunity against yellow fever in adults. Vaccine. 2014;32:4977–84.
28. Campi-Azevedo AC, Costa-Pereira C, Antonelli LR, Fonseca CT, Teixeira-Carvalho A, Villela-Rezende G, et al. Booster dose after 10 years is recommended following 17DD-YF primary vaccination. Hum Vaccin Immunother. 2016;12:491–502.
29. De Melo AB, da Paz MC, Magalhães M. Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. AmJTrop Med Hyg. 2011;85(4):739–47.
30. Hepburn MJ, Kortepeter MG, Pittman PR, Boudreau EF, Mangiafico JA, Buck PA, et al. Neutralizing antibody response to booster vaccination with the 17D yellow fever vaccine. Vaccine. 2006;24:2843–9.
31. Muyanja E, Ssemaganda A, Ngauv P, Cubas R, Perrin H, Srinivasan D, et al. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J Clin Invest. 2014;124:3147–58.
32. Jean K, Donnelly C, Ferguson N, Garske T. A Meta-analysis of serological response associated with yellow fever vaccination. Am J Trop Med Hyg. 2016;95(6):1435–9.
33. Amanna IJ, Slifka MK. Questions regarding the safety and duration of immunity following live yellow fever vaccination. Expert Rev Vaccines. 2016;15:1519–33.
34. Wold Health Organization. Yellow Fever Situation Report, 10.28.2016. http://apps.who.int/iris/bitstream/10665/250661/1/yellowfeversitrep28Oct16-eng.pdf?ua=1. 2016.
35. Grobbelaar AA, Weyer J, Moolla N, van Vuren PJ, Moises F, Paweska JT. Resurgence of yellow fever in Angola, 2015–2016. Emerg Infect Dis. 2016;22:1854–5.
36. •Barrett AD. Yellow fever in Angola and beyond—the problem of vaccine supply and demand. N Engl J Med. 2016;375:301–3. Discusses 17D vaccine production and formulation, as well as, alternative approaches to vaccination storages due to the Angola and concurrent outbreaks.
37. Chan M. Yellow fever: the resurgence of a forgotten disease. Lancet. 2016;387:2165–6.
38. Green A. Yellow fever continues to spread in Angola. Lancet. 2016;387:2493.
39. Wolrd Health Organization.World Yellow Fever Situation Report, 07.08.2016. http://apps.who.int/iris/bitstream/10665/246189/1/yellowsitrep-8Jul2016-eng.pdf. 2016.
40. World Health Organization. World Yellow Fever Situation Report, 05.08.2016 http://apps.who.int/iris/bitstream/10665/247198/1/yellowfeversitrep-5Aug2016-eng.pdf. 2016.
41. World Health Organization. WHO prequalified vaccines, 05.05.2016. https://extranet.who.int/gavi/PQ_Web/Browse.aspx?nav=3. 2016.
42. •• Campi-Azevedo AC, de Almeida EP, Coelho-Dos-Reis JG, Peruhype-Magalhães V, Willela-Rezende G, Quaresma PFF, et al. Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline. BMC Infect Dis. 2014;14:391. Follow-up to Martins et al. [43] study that undertakes a detailed study of the innate and adaptive immune response following sub-dose vaccination with 17DD.
43. •• Martins RM, de Maia ML, Farias RH, Camacho LA, Freire MS, Galler R, et al. 17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study. Hum Vaccin Immunother. 2013;9:879–88. Study of fractional dosing with 17DD sub-strain, concluding that subdoses as low as 587 IU induced comparable nuetralizing antibodies as a single dose.
44. World Health Organization Secretariat information paper. Fractional dose yellow fever vaccine as a dose-sparing option for outbreak response, 07.20.2016. http://www.who.int/iris/handle/10665/246236 2016